Interleukin‐6 and thrombopoietin concentrations in dogs with carcinoma with and without thrombocytosis

Cheney, Adrienne; Woolcock, Andrew D; Mukhopadhyay, Abhijit; Knapp, Deborah W.; Moore, George E.

doi:10.1111/jvim.16317

Cited by 2 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased platelet concentration identified in tumor-bearing dogs without hemorrhage in this study is most likely related to a combination of chronic inflammation, chronic consumption resulting in increased production, 65 and higher thrombopoietin production in dogs with carcinoma. 66 Cancer, particularly carcinoma, and inflammation were identified as the most and second most common causes of thrombocytosis in dogs. 67 In contrast, thrombocytopenia has been associated with hemangiosarcomas, 14 and DIC in tumor-bearing dogs.…”

Section: Discussionmentioning

confidence: 99%

A prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcoma

Pazzi,

Fosgate,

Rixon

et al. 2023

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundKnowledge of the prevalence of thromboemboli and the associated hemostatic status in dogs with carcinoma or sarcoma is unknown and might allow earlier intervention.ObjectivesEstimate prevalence of thromboemboli and their association with hemostatic changes in dogs with carcinomas or sarcomas; estimate predictive values of hemostatic variables for thromboembolic disease in tumor‐bearing dogs.AnimalsThirty‐two dogs with sarcoma, 30 with carcinoma, 20 healthy age‐controlled dogs.MethodsProspective cross‐sectional study. A hemostasis panel (platelet concentration, thromboelastography, fibrinogen and D‐dimer concentration, factor X, VII and antithrombin activity) was performed in all dogs. Tumor‐bearing dogs underwent complete post mortem and histopathological evaluation. Comparisons between healthy dogs and tumor‐bearing dogs with and without intracavitary hemorrhage; and tumor‐bearing dogs with and without microthrombi were analyzed.ResultsThromboembolic disease was identified in 32/62 (52%, 95% CI: 39%‐65%) tumor‐bearing dogs. Microthrombi were identified in 31/62 (50%, 95% CI: 37%‐63%) dogs, 21/31 (68%, 95% CI: 49%‐83%) had exclusively intra‐tumoral microthrombi, 10/31 (32%, 95% CI: 17%‐51%) had distant microthrombi. Macrothrombi were identified in 3 tumor‐bearing dogs. Hemostatic changes potentially consistent with overt and non‐overt disseminated intravascular coagulation were identified in some tumor‐bearing dogs. D‐dimer concentrations were significantly higher (P = .02) and platelet concentration significantly lower (P = .03) in tumor‐bearing dogs with microthrombi compared to tumor‐bearing dogs without microthrombi. D‐dimer concentration above 500 ng/mL was 80% sensitive and 41% specific for the prediction of microthrombi presence.ConclusionThe high microthrombi prevalence and concomitant hemostatic dysfunction in dogs with carcinomas or sarcomas has not previously been reported, though the clinical importance is unknown. Increased D‐dimer concentration might increase suspicion of microthrombi.

show abstract

Section: Discussionmentioning

confidence: 99%

A prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcoma

Pazzi,

Fosgate,

Rixon

et al. 2023

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

Plasma concentration of thrombopoietin in dogs with immune thrombocytopenia

Brooks,

Catalfamo

et al. 2024

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundImmune thrombocytopenia (ITP) is a common cause of severe thrombocytopenia in dogs. The pathogenesis of nonassociative, primary ITP (pITP) appears complex, with ill‐defined thrombopoietic response.ObjectivesDevelop an immunoassay to measure plasma canine thrombopoietin (TPO) concentration and characterize TPO concentrations in dogs with pITP.AnimalsForty‐one healthy dogs, 8 dogs in an induced ITP model (3 control, 5 ITP), and 58 pITP dogs.MethodsRecombinant canine TPO (rcTPO) was purchased and its identity confirmed by mass spectrometry. Monoclonal antibodies were raised to rcTPO and used to configure a sandwich ELISA using streptavidin‐biotin detection. Assay performance, coefficients of variability, and healthy dog plasma TPO reference interval (RI) were determined, followed by assay of ITP samples.ResultsAssay dynamic range was 15 pg/mL (lower limit of detection) to 1000 pg/mL TPO, with limit of quantitation of 62 pg/mL. Plasma TPO RI was 0 to 158 pg/mL, with plasma TPO <62 pg/mL for 35/41 healthy dogs. All dogs with induced ITP developed marked increases in plasma TPO concentration. Peak values ranged from 515 to >6000 pg/mL. In contrast, only 2/58 pITP dogs had TPO values above RI.Conclusions and Clinical ImportancePlasma TPO concentration is paradoxically low at diagnosis for most dogs with pITP. This finding suggests that ineffective thrombopoiesis contributes to thrombocytopenia in pITP dogs and supports evaluating TPO receptor agonist treatment as used for pITP in humans. The TPO assay provides a new tool to study thrombopoiesis in pITP and other thrombocytopenic syndromes in dogs.

show abstract

Interleukin‐6 and thrombopoietin concentrations in dogs with carcinoma with and without thrombocytosis

Cited by 2 publications

References 37 publications

A prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcoma

A prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcoma

Plasma concentration of thrombopoietin in dogs with immune thrombocytopenia

Contact Info

Product

Resources

About